Ascendis Pharma launches YUVIWEL with FDA orphan drug exclusivity for treating achondroplasia in children.

Ascendis Pharma announced that YUVIWEL (navepegritide) received orphan drug exclusivity from the U.S. FDA and is now commercially available in the U.S. This once-weekly treatment is the first FDA-approved therapy to increase growth in children aged 2 and older with achondroplasia. The exclusivity grants Ascendis seven years of market protection through 2033, supporting revenue growth as prescriptions are reimbursed. The company also offers patient support programs to assist families and healthcare providers during treatment.